| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Clerodendrin targets Interleukin-4 (IL-4) and β-hexosaminidase (Hex). It acts as a dual inhibitor, blocking the activity of both targets. By inhibiting IL-4, it modulates inflammatory responses. By inhibiting β-hexosaminidase, it interferes with various cellular processes.
|
|---|---|
| ln Vitro |
In RBL-2H3 cells, propidium iodide-induced IL-4 mRNA expression and β-hexosaminidase release are inhibited by cleodondrin (10 μM; 1 and 3 hours) [1].
In vitro, Clerodendrin (10 μM; 1 and 3 h) inhibits IL-4 mRNA expression and the release of β-hexosaminidase. It exhibits significant biological activity by modulating inflammatory responses. Its dual inhibition of IL-4 and Hex makes it a valuable tool for studying inflammatory and allergic diseases. |
| ln Vivo |
In vivo activity data for Clerodendrin is limited. As a potent IL-4 and Hex inhibitor, it is expected to have anti-inflammatory and anti-allergic effects. Its natural product origin suggests potential for further development.
|
| Enzyme Assay |
Clerodendrin is evaluated in cell-free enzymatic assays using purified IL-4 and β-hexosaminidase. The compound is incubated with the target protein, and the inhibition of activity is measured. IC50 values are determined to quantify the potency of inhibition.
|
| Cell Assay |
Clerodendrin is assessed in cell-based assays using immune cells. Cells are treated with Clerodendrin, and IL-4 mRNA expression and β-hexosaminidase release are measured. Its effects on inflammatory cytokine production and allergic responses are evaluated.
|
| Animal Protocol |
Clerodendrin is administered in animal models to evaluate its anti-inflammatory and anti-allergic effects. However, specific animal study protocols are not extensively documented. It is typically formulated for in vivo administration using DMSO or other suitable vehicles.
|
| ADME/Pharmacokinetics |
Clerodendrin has a molecular weight of 622.49 and a molecular formula of C27H26O17. It has a CAS number of 119738-57-7. The compound is a natural product. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Clerodendrin. The compound is for research use only and is not intended for human therapeutic use. It is a natural product and is generally considered safe for research purposes.
|
| References | |
| Additional Infomation |
According to reports, calendula extract is found in perilla, coleus, and other organisms with available data.
Clerodendrin is also known as Apigenin-7-O-glucuronopyranosyl(1-2)-glucuronopyranoside. It is a natural product isolated from Clerodendron trichotomm and Lobelia chinensis. The compound is not approved for clinical use. |
| Molecular Formula |
C27H26O17
|
|---|---|
| Molecular Weight |
622.48514
|
| Exact Mass |
622.117
|
| CAS # |
119738-57-7
|
| PubChem CID |
5488004
|
| Appearance |
White to off-white solid powder
|
| Density |
1.88g/cm3
|
| Boiling Point |
1057.6ºC at 760mmHg
|
| Flash Point |
349.9ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.766
|
| LogP |
-0.2
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
44
|
| Complexity |
1110
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)O)O
|
| InChi Key |
SJFTVAAHLRFBST-DBFWEQBMSA-N
|
| InChi Code |
InChI=1S/C27H26O17/c28-9-3-1-8(2-4-9)13-7-12(30)15-11(29)5-10(6-14(15)41-13)40-27-23(19(34)18(33)22(43-27)25(38)39)44-26-20(35)16(31)17(32)21(42-26)24(36)37/h1-7,16-23,26-29,31-35H,(H,36,37)(H,38,39)/t16-,17-,18-,19-,20+,21-,22-,23+,26-,27+/m0/s1
|
| Chemical Name |
(2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-6-carboxy-4,5-dihydroxy-2-[5-hydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6065 mL | 8.0323 mL | 16.0645 mL | |
| 5 mM | 0.3213 mL | 1.6065 mL | 3.2129 mL | |
| 10 mM | 0.1606 mL | 0.8032 mL | 1.6065 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
